Project Grant R43HL125015

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program provides $299,435 to support Halomine Inc., doing business as Avantguard, in developing a novel antifungal treatment based on stabilized chloramine technology. The key objectives are to: Test the minimum inhibitory and bactericidal concentrations (MIC/MBC) of the chloramine compound against a larger set of fungal strains that...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $314,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Via Therapeutics, LLC, a pharmaceutical research and development company based in Austin, Texas. The grant supports the development of an inhaled, fixed-dose combination powder product containing both azithromycin and amikacin for the treatment of non-tuberculous mycobacterial (NTM) infections. The goal is to improve...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Cyrus Biotechnology, Inc., a minority-owned small disadvantaged business located in Seattle, WA. The funding supports research to develop an engineered immunoglobulin G (IgG) protease enzyme for the treatment of immune thrombocytopenia (ITP) and other IgG-mediated autoimmune diseases. The key objectives are...

The National Science Foundation (NSF) awarded a $1,193,767 Cooperative Agreement under the Technology, Innovation, and Partnerships (CFDA 47.084) program to Xheme Inc., a for-profit company in Newton, MA. The grant supports the development of a novel, non-toxic blood bag technology to replace outdated polyvinyl chloride (PVC) bags that contain hazardous plasticizers. The project aims to create a next-generation composite blood bag that eliminates harmful leaching substances while meeting...

This $350,027 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) is for the development of a cost-effective, efficient, and generalizable water-based PLGA microsphere encapsulation technology for delivering commercial peptide drugs via monthly injections. The project aims to formulate and optimize sterile remote-loaded PLGA microspheres that can provide constant delivery of peptide drugs,...

This Project Grant award of $699,814 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research, aims to study molecular mechanisms of Plasmodium parasite invasion in Anopheles mosquito midguts to identify novel targets for transmission-blocking malaria vaccines. The key products and services to be delivered under this award include: Functional characterization of identified mosquito and parasite proteins that mediate...

This Project Grant award of $303,274 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports Antiger Therapeutics Inc., a startup biotech company, in developing targeted immunotherapies for Type 1 Diabetes (T1D). The primary objective is to engineer Peptide-HLA-DQ8 complex biologics that can selectively block the pathogenic T cells responsible for the autoimmune response in T1D. This innovative...

This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), is focused on the development of novel benzyl-piperidine antifungal agents to treat intractable Mucorales infections. The $299,946 award to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, MA, aims to chemically optimize a lead series of benzyl-piperidine compounds to improve their...

This $392,634 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel nanoimmunotherapeutic approach to combat multidrug-resistant (MDR) bacterial infections. The project aims to design, fabricate, and optimize a red blood cell membrane-coated, hemoglobin-encapsulating nanoparticle (RHNP) that can sensitize bacteria to host oxidant killing while...

This Project Grant award of $2,461,670.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the development of ErythroMer (EM), a dried, bio-inspired artificial red blood cell substitute, by Kalocyte Inc., a biotech startup. The project aims to optimize the lyophilization and reconstitution of EM to improve its oxygen binding and release properties, as well as evaluate its efficacy, pharmacokinetics, dosing, and compatibility with...